Drug combo shows promise for non–clear cell renal cell carcinomaSeptember 6, 2016Genitourinary CancerRenal Cell Carcinoma
Active surveillance may be feasible for some advanced RCC patientsAugust 12, 2016Genitourinary CancerRenal Cell Carcinoma
Gene profile predicts RCC response to nivolumabAugust 4, 2016Genitourinary CancerImmuno-oncologyRenal Cell Carcinoma
First-in-class agent shows early promise in treating clear cell renal cell carcinomaJuly 27, 2016Genitourinary CancerRenal Cell Carcinoma
Cabozantinib improves overall survival in renal cell carcinomaJuly 20, 2016Genitourinary CancerRenal Cell Carcinoma
SU2C announces researcher-industry collaboration on immunotherapyJuly 13, 2016Genitourinary CancerHead & Neck/Thyroid CancersMelanomaImmuno-oncologyRenal Cell Carcinoma
Immune agonist, checkpoint inhibitor combo shows good tolerabilityJune 15, 2016Genitourinary CancerBreast CancerLung CancerMelanomaRenal Cell Carcinoma
FDA grants accelerated approval to nivolumab for Hodgkin lymphomaMay 17, 2016Lymphoma & Plasma Cell DisordersRenal Cell Carcinoma
FDA approves lenvatinib for advanced renal cell carcinomaMay 16, 2016Genitourinary CancerRenal Cell Carcinoma
Immune checkpoint inhibitors have antitumor activity in gastric, esophageal cancersJanuary 28, 2016GastroenterologyRenal Cell CarcinomaGastrointestinal Cancer
Individualized approach improves surveillance after renal cell carcinoma resectionSeptember 8, 2015Genitourinary CancerRare DiseasesRenal Cell Carcinoma
Nivolumab benefits patients with previously treated renal cell carcinomaMarch 23, 2015GastroenterologyRenal Cell CarcinomaGastrointestinal Cancer
